The webinar will feature presentations from Key Opinion Leaders Dr. Dave Nichols, MD  and Dr. Saima Aslam, MD who will discuss phage therapy, the current treatment landscape, and unmet medical need in cystic fibrosis patients with chronic Pseudomonas aeruginosa (PsA) pulmonary infections.

BiomX CEO, Jonathan Solomon, will present the company’s product candidate, BX004, as a potential treatment option. BX004 has been specifically designed to target PsA, a common cause of pulmonary infections and a main contributor to morbidity and mortality in patients with CF.

 A live question and answer session will follow.